ID   ZN335_HUMAN             Reviewed;        1342 AA.
AC   Q9H4Z2; B4DLG7; Q548D0; Q9H684;
DT   23-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   28-JUN-2023, entry version 184.
DE   RecName: Full=Zinc finger protein 335;
DE   AltName: Full=NRC-interacting factor 1;
DE            Short=NIF-1;
GN   Name=ZNF335;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION,
RP   INTERACTION WITH NCOA6, AND TISSUE SPECIFICITY.
RC   TISSUE=Teratocarcinoma;
RX   PubMed=12215545; DOI=10.1128/mcb.22.19.6883-6894.2002;
RA   Mahajan M.A., Murray A., Samuels H.H.;
RT   "NRC-interacting factor 1 is a novel cotransducer that interacts with and
RT   regulates the activity of the nuclear hormone receptor coactivator NRC.";
RL   Mol. Cell. Biol. 22:6883-6894(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT THR-294.
RC   TISSUE=Kidney epithelium, and Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [4]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [5]
RP   FUNCTION, AND INTERACTION WITH CNOT6 AND CNOT9.
RX   PubMed=18180299; DOI=10.1074/jbc.m706986200;
RA   Garapaty S., Mahajan M.A., Samuels H.H.;
RT   "Components of the CCR4-NOT complex function as nuclear hormone receptor
RT   coactivators via association with the NRC-interacting Factor NIF-1.";
RL   J. Biol. Chem. 283:6806-6816(2008).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1153, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   FUNCTION, IDENTIFICATION IN A NUCLEAR RECEPTOR HORMONE COMPLEX,
RP   IDENTIFICATION IN A HISTONE METHYLATION COMPLEX, AND INTERACTION WITH
RP   CCAR2; EMSY; RBBP5; ASH2L; WDR5; HCFC1 AND MKI67.
RX   PubMed=19131338; DOI=10.1074/jbc.m805872200;
RA   Garapaty S., Xu C.F., Trojer P., Mahajan M.A., Neubert T.A., Samuels H.H.;
RT   "Identification and characterization of a novel nuclear protein complex
RT   involved in nuclear hormone receptor-mediated gene regulation.";
RL   J. Biol. Chem. 284:7542-7552(2009).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-992 AND SER-1007, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [10]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1022, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [11]
RP   VARIANT MCPH10 HIS-1111, CHARACTERIZATION OF VARIANT MCPH10 HIS-1111,
RP   FUNCTION IN NEUROGENESIS, INTERACTION WITH ASH2L; CXXC1; KMT2A/MLL1; MKI67;
RP   RBBP5; SETD1A AND WDR5, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=23178126; DOI=10.1016/j.cell.2012.10.043;
RA   Yang Y.J., Baltus A.E., Mathew R.S., Murphy E.A., Evrony G.D.,
RA   Gonzalez D.M., Wang E.P., Marshall-Walker C.A., Barry B.J., Murn J.,
RA   Tatarakis A., Mahajan M.A., Samuels H.H., Shi Y., Golden J.A., Mahajnah M.,
RA   Shenhav R., Walsh C.A.;
RT   "Microcephaly gene links trithorax and REST/NRSF to control neural stem
RT   cell proliferation and differentiation.";
RL   Cell 151:1097-1112(2012).
CC   -!- FUNCTION: Component or associated component of some histone
CC       methyltransferase complexes may regulate transcription through
CC       recruitment of those complexes on gene promoters (PubMed:19131338,
CC       PubMed:23178126). Enhances ligand-dependent transcriptional activation
CC       by nuclear hormone receptors (PubMed:12215545, PubMed:18180299,
CC       PubMed:19131338). Plays an important role in neural progenitor cell
CC       proliferation and self-renewal through the regulation of specific genes
CC       involved brain development, including REST (PubMed:23178126). Also
CC       controls the expression of genes involved in somatic development and
CC       regulates, for instance, lymphoblast proliferation (PubMed:23178126).
CC       {ECO:0000269|PubMed:12215545, ECO:0000269|PubMed:18180299,
CC       ECO:0000269|PubMed:19131338, ECO:0000269|PubMed:23178126}.
CC   -!- SUBUNIT: Interacts with NCOA6; may enhance ligand-dependent
CC       transcriptional activation by nuclear hormone receptors
CC       (PubMed:12215545). Interacts with CNOT6 (PubMed:18180299). Interacts
CC       with CNOT9; the interaction is direct (PubMed:18180299). Component of a
CC       nuclear receptor-mediated transcription complex composed of at least
CC       ZNF335, CCAR2 and EMSY; the complex stimulates the transcription of
CC       nuclear receptor target genes such as SOX9 and HOXA1 (PubMed:19131338).
CC       Within the complex interacts with EMSY and interacts (via C-terminus)
CC       with CCAR2 (PubMed:19131338). Interacts with members of histone
CC       H3'Lys4'(H3K4) methyltransferase complexes ASH2L, CXXC1, KMT2A/MLL1,
CC       RBBP5, SETD1A and WDR5 (PubMed:23178126). Component of a histone
CC       methylation complex composed of at least ZNF335, RBBP5, ASH2L and WDR5;
CC       the complex may have histone H3-specific methyltransferase activity,
CC       however does not have specificity for 'Lys-4' of histone H3
CC       (PubMed:19131338). Interacts with RBBP5 and WDR5 (PubMed:19131338).
CC       Interacts with ASHL2 (PubMed:19131338). Components of this complex may
CC       associate with components of the ZNF335-CCAR2-EMSY nuclear receptor-
CC       mediated transcription complex to form a complex at least composed of
CC       ZNF335, HCFC1, CCAR2, EMSY, MKI67, RBBP5, ASH2L and WDR5
CC       (PubMed:19131338). Within this complex also interacts with HCFC1 and
CC       MKI67 (PubMed:19131338). {ECO:0000269|PubMed:12215545,
CC       ECO:0000269|PubMed:18180299, ECO:0000269|PubMed:19131338,
CC       ECO:0000269|PubMed:23178126}.
CC   -!- INTERACTION:
CC       Q9H4Z2; Q8N163: CCAR2; NbExp=5; IntAct=EBI-2795590, EBI-355410;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12215545}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9H4Z2-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9H4Z2-2; Sequence=VSP_035791, VSP_035792;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed.
CC       {ECO:0000269|PubMed:12215545, ECO:0000269|PubMed:23178126}.
CC   -!- DEVELOPMENTAL STAGE: Widely expressed in fetal tissues including fetal
CC       brain. {ECO:0000269|PubMed:23178126}.
CC   -!- DISEASE: Microcephaly 10, primary, autosomal recessive (MCPH10)
CC       [MIM:615095]: A form of microcephaly, a disease defined as a head
CC       circumference more than 3 standard deviations below the age-related
CC       mean. Brain weight is markedly reduced and the cerebral cortex is
CC       disproportionately small. MCPH10 is characterized by extremely small
CC       head size and death usually by 1 year of age. Neuropathologic
CC       examination shows severe loss of neurons as well as neuronal loss of
CC       polarity and abnormal dendritic maturation.
CC       {ECO:0000269|PubMed:23178126}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the krueppel C2H2-type zinc-finger protein
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB15379.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF395833; AAN09900.1; -; mRNA.
DR   EMBL; AK026157; BAB15379.1; ALT_INIT; mRNA.
DR   EMBL; AK296989; BAG59529.1; -; mRNA.
DR   EMBL; AL162458; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS13389.1; -. [Q9H4Z2-1]
DR   RefSeq; NP_071378.1; NM_022095.3. [Q9H4Z2-1]
DR   AlphaFoldDB; Q9H4Z2; -.
DR   BioGRID; 121994; 22.
DR   CORUM; Q9H4Z2; -.
DR   IntAct; Q9H4Z2; 21.
DR   STRING; 9606.ENSP00000325326; -.
DR   GlyCosmos; Q9H4Z2; 1 site, 1 glycan.
DR   GlyGen; Q9H4Z2; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9H4Z2; -.
DR   PhosphoSitePlus; Q9H4Z2; -.
DR   BioMuta; ZNF335; -.
DR   DMDM; 20141037; -.
DR   EPD; Q9H4Z2; -.
DR   jPOST; Q9H4Z2; -.
DR   MassIVE; Q9H4Z2; -.
DR   MaxQB; Q9H4Z2; -.
DR   PaxDb; Q9H4Z2; -.
DR   PeptideAtlas; Q9H4Z2; -.
DR   ProteomicsDB; 80883; -. [Q9H4Z2-1]
DR   ProteomicsDB; 80884; -. [Q9H4Z2-2]
DR   Antibodypedia; 27906; 139 antibodies from 28 providers.
DR   DNASU; 63925; -.
DR   Ensembl; ENST00000322927.3; ENSP00000325326.2; ENSG00000198026.8. [Q9H4Z2-1]
DR   GeneID; 63925; -.
DR   KEGG; hsa:63925; -.
DR   MANE-Select; ENST00000322927.3; ENSP00000325326.2; NM_022095.4; NP_071378.1.
DR   UCSC; uc002xqw.4; human. [Q9H4Z2-1]
DR   AGR; HGNC:15807; -.
DR   CTD; 63925; -.
DR   DisGeNET; 63925; -.
DR   GeneCards; ZNF335; -.
DR   HGNC; HGNC:15807; ZNF335.
DR   HPA; ENSG00000198026; Low tissue specificity.
DR   MalaCards; ZNF335; -.
DR   MIM; 610827; gene.
DR   MIM; 615095; phenotype.
DR   neXtProt; NX_Q9H4Z2; -.
DR   OpenTargets; ENSG00000198026; -.
DR   Orphanet; 329228; Microcephalic primordial dwarfism due to ZNF335 deficiency.
DR   PharmGKB; PA38041; -.
DR   VEuPathDB; HostDB:ENSG00000198026; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   GeneTree; ENSGT00940000158508; -.
DR   HOGENOM; CLU_006340_0_0_1; -.
DR   InParanoid; Q9H4Z2; -.
DR   OMA; HKRAHVG; -.
DR   OrthoDB; 4239435at2759; -.
DR   PhylomeDB; Q9H4Z2; -.
DR   TreeFam; TF332472; -.
DR   PathwayCommons; Q9H4Z2; -.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   SignaLink; Q9H4Z2; -.
DR   BioGRID-ORCS; 63925; 515 hits in 1187 CRISPR screens.
DR   ChiTaRS; ZNF335; human.
DR   GenomeRNAi; 63925; -.
DR   Pharos; Q9H4Z2; Tbio.
DR   PRO; PR:Q9H4Z2; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; Q9H4Z2; protein.
DR   Bgee; ENSG00000198026; Expressed in granulocyte and 125 other tissues.
DR   Genevisible; Q9H4Z2; HS.
DR   GO; GO:0035097; C:histone methyltransferase complex; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:1990226; F:histone methyltransferase binding; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; ISS:UniProtKB.
DR   GO; GO:0007420; P:brain development; IMP:UniProtKB.
DR   GO; GO:0048854; P:brain morphogenesis; IEA:Ensembl.
DR   GO; GO:0021895; P:cerebral cortex neuron differentiation; IEA:Ensembl.
DR   GO; GO:0040029; P:epigenetic regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0048812; P:neuron projection morphogenesis; ISS:UniProtKB.
DR   GO; GO:0050671; P:positive regulation of lymphocyte proliferation; IMP:UniProtKB.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; ISS:UniProtKB.
DR   GO; GO:0050769; P:positive regulation of neurogenesis; IMP:UniProtKB.
DR   GO; GO:0010468; P:regulation of gene expression; IBA:GO_Central.
DR   Gene3D; 3.30.160.60; Classic Zinc Finger; 7.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR24403; ZINC FINGER PROTEIN; 1.
DR   PANTHER; PTHR24403:SF36; ZINC FINGER PROTEIN 335; 1.
DR   Pfam; PF13894; zf-C2H2_4; 1.
DR   Pfam; PF13909; zf-H2C2_5; 1.
DR   SMART; SM00355; ZnF_C2H2; 13.
DR   SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 7.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 6.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 13.
PE   1: Evidence at protein level;
KW   Activator; Alternative splicing; Developmental protein; Disease variant;
KW   DNA-binding; Intellectual disability; Isopeptide bond; Metal-binding;
KW   Nucleus; Phosphoprotein; Primary microcephaly; Reference proteome; Repeat;
KW   Transcription; Transcription regulation; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..1342
FT                   /note="Zinc finger protein 335"
FT                   /id="PRO_0000047538"
FT   ZN_FING         245..268
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         465..487
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         495..517
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         523..545
FT                   /note="C2H2-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         562..584
FT                   /note="C2H2-type 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         590..612
FT                   /note="C2H2-type 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         621..643
FT                   /note="C2H2-type 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         649..672
FT                   /note="C2H2-type 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         678..701
FT                   /note="C2H2-type 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         1019..1041
FT                   /note="C2H2-type 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         1047..1069
FT                   /note="C2H2-type 11"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         1075..1097
FT                   /note="C2H2-type 12"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         1103..1126
FT                   /note="C2H2-type 13"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          1..102
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          201..228
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          274..442
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          732..763
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          964..1013
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1041..1342
FT                   /note="Involved in the interaction with CCAR2"
FT                   /evidence="ECO:0000269|PubMed:19131338"
FT   COMPBIAS        53..95
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        297..325
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        740..754
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        981..996
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         976
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:G3V893"
FT   MOD_RES         992
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1007
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1153
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   CROSSLNK        1022
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..155
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_035791"
FT   VAR_SEQ         156..173
FT                   /note="EDGGAETTRYLILQGPDD -> MATSSMPESERNVATKAS (in isoform
FT                   2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_035792"
FT   VARIANT         65
FT                   /note="R -> C (in dbSNP:rs6130982)"
FT                   /id="VAR_047560"
FT   VARIANT         101
FT                   /note="G -> S (in dbSNP:rs6094231)"
FT                   /id="VAR_047561"
FT   VARIANT         294
FT                   /note="S -> T (in dbSNP:rs6032606)"
FT                   /evidence="ECO:0000269|PubMed:14702039"
FT                   /id="VAR_024211"
FT   VARIANT         603
FT                   /note="Y -> H (in dbSNP:rs16990961)"
FT                   /id="VAR_047562"
FT   VARIANT         1111
FT                   /note="R -> H (in MCPH10; hypomorphic mutation; may cause
FT                   altered transcript but some full-length protein is still
FT                   formed; dbSNP:rs397514642)"
FT                   /evidence="ECO:0000269|PubMed:23178126"
FT                   /id="VAR_069469"
FT   CONFLICT        227
FT                   /note="E -> G (in Ref. 2; BAG59529)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1342 AA;  144893 MW;  6D230DEE0B3AE670 CRC64;
     MEENEVESSS DAAPGPGRPE EPSESGLGVG TSEAVSADSS DAAAAPGQAE ADDSGVGQSS
     DRGSRSQEEV SESSSSADPL PNSYLPDSSS VSHGPVAGVT GGPPALVHSS ALPDPNMLVS
     DCTASSSDLG SAIDKIIEST IGPDLIQNCI TVTSAEDGGA ETTRYLILQG PDDGAPMTSP
     MSSSTLAHSL AAIEALADGP TSTSTCLEAQ GGPSSPVQLP PASGAEEPDL QSLEAMMEVV
     VVQQFKCKMC QYRSSTKATL LRHMRERHFR PVAAAAAAAG KKGRLRKWST STKSQEEEGP
     EEEDDDDIVD AGAIDDLEED SDYNPAEDEP RGRQLRLQRP TPSTPRPRRR PGRPRKLPRL
     EISDLPDGVE GEPLVSSQSG QSPPEPQDPE APSSSGPGHL VAMGKVSRTP VEAGVSQSDA
     ENAAPSCPDE HDTLPRRRGR PSRRFLGKKY RKYYYKSPKP LLRPFLCRIC GSRFLSHEDL
     RFHVNSHEAG DPQLFKCLQC SYRSRRWSSL KEHMFNHVGS KPYKCDECSY TSVYRKDVIR
     HAAVHSRDRK KRPDPTPKLS SFPCPVCGRV YPMQKRLTQH MKTHSTEKPH MCDKCGKSFK
     KRYTFKMHLL THIQAVANRR FKCEFCEFVC EDKKALLNHQ LSHVSDKPFK CSFCPYRTFR
     EDFLLSHVAV KHTGAKPFAC EYCHFSTRHK KNLRLHVRCR HASSFEEWGR RHPEEPPSRR
     RPFFSLQQIE ELKQQHSAAP GPPPSSPGPP EIPPEATTFQ SSEAPSLLCS DTLGGATIIY
     QQGAEESTAM ATQTALDLLL NMSAQRELGG TALQVAVVKS EDVEAGLASP GGQPSPEGAT
     PQVVTLHVAE PGGGAAAESQ LGPPDLPQIT LAPGPFGGTG YSVITAPPME EGTSAPGTPY
     SEEPAGEAAQ AVVVSDTLKE AGTHYIMATD GTQLHHIELT ADGSISFPSP DALASGAKWP
     LLQCGGLPRD GPEPPSPAKT HCVGDSQSSA SSPPATSKAL GLAVPPSPPS AATAASKKFS
     CKICAEAFPG RAEMESHKRA HAGPGAFKCP DCPFSARQWP EVRAHMAQHS SLRPHQCSQC
     SFASKNKKDL RRHMLTHTKE KPFACHLCGQ RFNRNGHLKF HIQRLHSPDG RKSGTPTARA
     PTQTPTQTII LNSDDETLAT LHTALQSSHG VLGPERLQQA LSQEHIIVAQ EQTVTNQEEA
     AYIQEITTAD GQTVQHLVTS DNQVQYIISQ DGVQHLLPQE YVVVPEGHHI QVQEGQITHI
     QYEQGAPFLQ ESQIQYVPVS PGQQLVTQAQ LEAAAHSAVT AVADAAMAQA QGLFGTDETV
     PEHIQQLQHQ GIEYDVITLA DD
//
